rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Lux Venture Partners V, LLC

10% owner

Company insider

Files Form 4 as: 10% owner, Eikon Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
15
Buys
1
Sells
0
Bought
$5.0M
Sold
$0
Companies
1
Companies where not an officer
1
First trade
4 Feb 2026
Last trade
6 Feb 2026
Last filed
6 Feb 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
EIKN Eikon Therapeutics10% owner · Biotechnology · last 6 Feb 20261 buy · 0 sells

Activity over time

1 Feb – 1 Oct
01Feb 26Apr 26Jun 26Aug 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
6 Feb 2026filed 6 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—530,920filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—5,289,322filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—3,526,215filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—303,360filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—1,450,614filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—10,266,152filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon TherapeuticsBiotechnologySEC FORM 4 Code C—2,387,705filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon TherapeuticsBiotechnologySEC FORM 4 Code C—1,151,540filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon TherapeuticsBiotechnologySEC FORM 4 Code C—2,155,765filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—10,000,000filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—7,807,026filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—2,502,252filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—796,380filing
4 Feb 2026filed 6 Feb 2026EIKN Eikon TherapeuticsBiotechnologySEC FORM 4 Bought$2.5M138,888 at $18.00filing
4 Feb 2026filed 6 Feb 2026EIKN Eikon TherapeuticsBiotechnologySEC FORM 4 Bought$2.5M138,888 at $18.00filing

Sectors

Health Care1

Buys in green, sells in red, by the company’s sector.

Related people

Tim KutzkeyDirector and 10% owner · 10% owner at Eikon Therapeutics, filing Form 4 there in the last year
Column Group IV GP, LP10% owner · 10% owner at Eikon Therapeutics, filing Form 4 there in the last year
Roy D. BaynesDirector · Chief Medical Officer at Eikon Therapeutics, filing Form 4 there in the last year
Kenneth C. FrazierDirector · Director at Eikon Therapeutics, filing Form 4 there in the last year
Roger M. PerlmutterDirector and Officer · Insider at Eikon Therapeutics, filing Form 4 there in the last year